side effects of long term tirzepatide use is a groundbreaking, once-weekly injectable medication that acts as a dual GIP and GLP-1 receptor agonist. Marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, it mimics Semaglutide vs Tirzepatide: Which GLP-1

In the SURMOUNT-5 head-to-head trial comparing Zepbound directly to Wegovy, participants on Zepbound lost an average of 20.2% of body weight compared to 13.7% on Wegovy over 72 weeks, a 47% greater relative weight loss

These higher dosages are possible to achieve in mice, since they cannot complain to scientists about side effects occurring at high dosages and do not have the physical capability to prevent themselves from receiving drug injections) Sanofi produced a triple agonist , SAR441255, which was capable of decreasing body weight in mice by around 14% at 26 days, 12% in monkeys by 42 days [34] , although Sanofi have since discontinued development of the triple agonist for human use for uncited reasons

While low-carb diets are popular, you do not need to cut out carbohydrates to succeed on GLP-1 meds

2008;5(10):e197 67